TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed invasive breast cancer with stage IV disease, according to AJCC 6th edition (American Joint Committee on Cancer), either biopsy proven or with unequivocal evidence of metastatic disease by physical examination or radiological study~* All tumors must be ER-, PGR- and HER2-negative~* 18 years of age or older~* Paraffin tissue block is required from the primary tumor tissue or from diagnostic metastatic biopsy at time of relapse~* Measurable disease by RECIST~* Performance status of 0,1 or 2 by ECOG criteria (Eastern Cooperative Oncology Group)~* Life expectancy greater than 12 weeks~* Normal organ and bone marrow function documented within 14 days prior to enrollment as defined by the protocol~Exclusion Criteria:~* More than 1 prior chemotherapy for the treatment of recurrent or metastatic breast cancer~* Prior treatment with cisplatin, carboplatin, or other platinum chemotherapy agents~* Active brain metastases or unevaluated neurological symptoms suggestive of brain metastases~* Intercurrent illness or other major medical condition or comorbid condition that might affect study participation~* Significant history of uncontrolled cardiac disease such as uncontrolled hypertension, unstable angina, recent myocardial infarction, uncontrolled congestive heart failure, cardiomyopathy either symptomatic or asymptomatic but with decreased ejection fraction \<45%~* Renal dysfunction for which cisplatin dose would either require dose modification or would be considered unsafe~* Pregnant or nursing women~* History or other malignancy that was not treated with curative intent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Cisplatin or carboplatin (1 arm, 2 cohorts)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Anticoagulation in Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* inclusion in the trial with clinicaltrials.gov identifier NCT02610933~* signed informed consent for this extension trial~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Hemodialysis patients with non valvular atrial fibrillation receiving warfarin
- rivaroxaban (Type: EXPERIMENTAL): Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od
- rivaroxaban + K2 (Type: EXPERIMENTAL): Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od + vitamin K2 supplements

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Physical Therapist as Primary Assessor for Patients With Knee Pain in Primary Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>38 years old~* Knee pain most of the days the last month~* Crepitus on active motion~* Morning stiffness, duration less than 30 minutes~* The patient has to understand the Swedish language to follow test instructions and to complete the self-administered questionnaires.~Exclusion Criteria:~* Already been assessed/diagnosed by a healthcare provider for current knee pain.~* knee pain due to a traumatic cause~* other rheumatic or systemic diseases~* severe somatic or mental disease~* pregnancy.

- Gender: ALL
- Minimum Age: 38 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Physical therapy assessment (Type: OTHER): Patients allocated to the intervention group will be assigned to an assessment and evaluation by a physical therapist. If they are diagnosed with knee osteoarthritis they will get an offer to participate in a patient education program and physical training with an individualized exercise program made by a physical therapist. Patients will be offered individual treatment if they decline to participate in the education program, or if they have another diagnosis than osteoarthritis. Anytime after the first assessment by the physical therapist, the patient will be able to contact a physician if they want to.
- Physician assessment (Type: OTHER): Allocation to the control group will involve an assessment and evaluation made by a physician. Further measures will then be determined by attending physician and the procedures that might get included are drug prescriptions, referral to x-ray examination, referral to a physical therapist or another health care provider. Anytime after the first assessment by the physician, the patient will be able to contact a physical therapist if they want to, even though if they have not been referred by the physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of atopic dermatitis that has been present for at least 3 years before the screening visit~* Investigator's Global Assessment (IGA) score of \>/= 3 at the screening and baseline visits~* \>/= 15% body surface area (BSA) of AD involvement at the screening and baseline visits~* History of inadequate response to a stable (\>/= 1 month) regimen of topical corticosteroids or calcineurin inhibitors as treatment for AD within 3 months before the screening visit~* Willing and able to comply with clinic visits and study-related procedures~* Patient able to read and understand, and willing to sign the informed consent form~Exclusion Criteria:~* A positive QuantiFERON® - TB (tuberculosis) Gold Test at the screening visit~* Known history of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C and/or positive Hepatitis B surface antigen (HBsAg), positive Hepatitis C antibody (HCV)~* Treatment with an investigational drug within 8 weeks before the baseline visit~* Treatment with leukotriene inhibitors within 4 weeks before the baseline visit~* Treatment with systemic corticosteroids within 4 weeks before the baseline visit~* Treatment with topical corticosteroids, tacrolimus, and/or pimecrolimus within 1 week before the baseline visit~* Systemic treatment for AD with an immunosuppressive/immunomodulating substance within 4 weeks before the baseline visit~* Chronic or acute infection requiring treatment~* History of clinical parasite infection, other than treated trichomoniasis~* History of malignancy within 5 years before the baseline visit~* Any medical or psychiatric condition which, in the opinion of the investigator or the sponsor's medical monitor, would place the patient at risk, interfere with participation in the study, or interfere with the interpretation of study results~* Pregnant or breast-feeding women~* Unwilling to use adequate birth control, if of reproductive potential and sexually active

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): None
- Cohort 2 (Type: EXPERIMENTAL): None
- Cohort 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexlansoprazole MR-Based Concomitant Quadruple Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~H. pylori-infected outpatients with endoscopically proven peptic ulcer diseases or gastritis.~Exclusion Criteria:~1. Previous H. pylori-eradication therapy~2. ingestion of antibiotics, bismuth, or PPIs within the prior 4 weeks~3. patients with allergic history to the medications used~4. patients with previous gastric surgery~5. the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)~6. pregnant women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dexlansoprazole MR group (Type: EXPERIMENTAL): Dexlansoprazole MR 60 mg qd.,clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
- lansoprazole group (Type: EXPERIMENTAL): Lansoprazole 30 mg bid., clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TAP Block With Liposomal Bupivacaine Versus Bupivacaine in Robotic Hysterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* those who present for elective robotic assisted hysterectomy~Exclusion Criteria:~* non english speaking~* chronic pain~* on opioids greater than 1 weeks~* chronic anticoagulation~* allergy to local anesthetics~* use of spinal or epidural for surgery~* lack of patient cooperation~* contraindication to regional anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- liposomal bupivacaine TAP (Type: EXPERIMENTAL): these patients receive a subcostal TAP with liposomal bupivacaine
- bupivacaine TAP (Type: ACTIVE_COMPARATOR): These patients receive a subcostal TAP with bupivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: Patients must be greater than or equal to 365 days and less than 23 years of age at the time of enrollment.~2. Diagnosis: Patients with any malignancy who will receive high dose methotrexate (HDMTX) given as a 5 g/m2 infusion over 24 hours and a history of ≥ 1 of the following:~   * Documented decreased renal function, defined as Creatinine greater than 1.5 x baseline or glomerular filtration rate (GFR) \<65ml/min/1.73m2.~  * History of prior nephrotoxicity with HDMTX as evidence by increased creatinine to 1.5 x baseline or need for dialysis or carboxypeptidase~  * History of Grade 3 adverse event (AE) related to HDMTX (mucositis, myelosuppression, nephrotoxicity, hepatotoxicity) based on the NIH Common Terminology Criteria for Adverse Events (CTCAE) version 4.0~  * Provider concern patient is at risk for MTX toxicity, such as a prior history of treatment with nephrotoxic chemotherapy, history of HDMTX-related neurotoxicity, or antimicrobial/antifungal therapy~Exclusion Criteria:~1. Unable to draw labs for HDMTX serum concentration~2. Enrollment on a protocol (COG or other) which restricts proposed dose modifications~3. Patients with Trisomy 21~4. Patients with greater than grade 1 neurologic toxicity at the time of enrollment that is attributed to unresolved prior methotrexate toxicity~5. Patients with greater than or equal to grade 3 chronic kidney disease at enrollment (eGFR or creatine clearance (CrCl) less than 30ml/min/1.73m2)

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- Individualized High Dose Methotrexate (Type: EXPERIMENTAL): Individualized high dose methotrexate given as a 24-hour infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of chronic moderate-to-severe atopic dermatitis (AD) for at least 1 year~* Recent history of inadequate response to medicated topical therapy for AD or required systemic therapy to control disease~* Moderate-to-severe AD defined as affected BSA at least 10%, IGA at least 3, EASI at least 16, Peak Pruritus NRS at least 4~Exclusion Criteria:~* A current or past medical history of conditions associated with thrombocytopenia, coagulopathy, or platelet dysfunction~* Currently have active forms of other inflammatory skin diseases, i.e. not AD, or have evidence of skin conditions (e.g. psoriasis, seborrheic dermatitis, lupus) at the time of Day 1 that would interfere with evaluation of AD or response to treatment~* Participants who have received prior treatment with any systemic JAK inhibitors~* Require treatment with prohibited concomitant medication(s) or have received a prohibited concomitant medication within specified time frames prior to the first dose of study medication, including topical treatments that could affect AD~* Pregnant or breastfeeding women or sexually-active women of childbearing potential who are unwilling to use contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-04965842 200 mg (Type: EXPERIMENTAL): None
- PF-04965842 100 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type IIb dyslipidemia.~Exclusion Criteria:~* Known hypersensitivity to fibrates or ezetimibe. Pregnant or lactating women. Contra-indication to fenofibrate or ezetimibe.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must present with non-Hodgkins Lymphoma (Low, Intermediate or High Grade) or Hodgkins Disease, CLL or Multiple Myeloma~* Life expectancy \> 6 months with Karnofsky Performance Index of \> =70~* Evaluable lesion as objective indicator of response~* Scheduled for at least one myelosuppressive cytotoxic regimen (experimental chemotherapy allowed) for at least 4-6 months~* Patients with reproductive potential must have used an adequate contraceptive method~* Transferrin saturation = 20% and serum ferritin = 50 ng/mL Bone marrow evaluations may be performed to determine if iron stores are adequate~* histologic documentation of disease.~Exclusion Criteria:~* Patients with no second active malignancy or history of other malignancy diagnosed within preceding 5 years (other than basal cell carcinoma or cervical cancer)~* No uncontrolled hypertension~* active, unresolved infection~* anemia due to factors other than cancer/chemotherapy, i.e., iron, folate, hemolysis, or GI bleeding~* Receiving Epoetin alfa independent of protocol~* Received chemotherapy with the previous 14 days~* Prior total lymphoid, extensive abdominal or inverted Y radiation therapy~* No use of interferons or interleukins during study~* No use of nonchemotherapy experimental agents within preceding 30 days~* No Hodgkins Disease patients who are chemotherapy naïve~* Received stem cell transplant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Controlled Trial: 5-day Course of Rifampin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria were:~* Adults aged 18 years or older~* A fever of higher than 37.5°C~* The concurrent presence of eschar or a maculopapular skin rash; and the clear presence of more than two symptoms such as headache, malaise, myalgia, coughing, nausea and abdominal discomfort.~* Patients were hospitalized at Chosun University Hospital in Kwangju, Korea or one of its two community-based affiliated hospitals which are all located in southwestern Korea between 2006 and 2009.~Exclusion Criteria:~The exclusion criteria were:~* An inability to take oral medications~* Pregnancy~* Hypersensitivity to the trial drugs~* Previous drug therapy with potential antirickettsial activity (e.g., rifampicin, chloramphenicol, macrolides, fluoroquinolones or tetracyclines) within 48 h prior to admission~* Severe scrub typhus (shock requiring vasopressor therapy for more than one hour~* A stuporous or comatose level of consciousness~* Respiratory failure requiring mechanical ventilation or renal failure requiring immediate dialysis) (4, 10).~* For the differential diagnosis of scrub typhus from other diseases with similar symptoms (e.g., murine typhus, leptospirosis, hemorrhagic fever with renal syndrome and systemic lupus erythematosus), patients underwent diagnostic tests. We thus excluded patients with concurrent infections who had the risk of causing different outcomes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): a 5-day course of daily 200-mg doses of doxycycline
- 2 (Type: ACTIVE_COMPARATOR): a 5-day course of daily 600-mg doses of rifampin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is less than 9 years old for girls and less than 10 years old for boys at initiation of triptorelin treatment or at the time of signing the informed consent.~* Participant must present evidence of CPP documented by:~* Onset of development of secondary sex characteristics (breast development in girls or testicular enlargement in boys according to the Tanner method: Stage II) before the age of 8 years in girls and 9 years in boys.~* Pubertal response of LH to GnRH stimulation test (stimulated peak LH ≥6 IU/L) in both sexes.~* Difference between bone age (BA) and CA \>1 year.~* Girls with Tanner staging ≥2 for breast development and who have enlarged uterine length and/or ovarian volume and at last 2 follicles with diameter \>4 mm in the ovary observed by pelvic type B ultrasound at the Screening visit; boys who have testicular volume ≥4 mL observed by testicular orchidometer at the Screening visit.~* Girls who have already had menophania/menarche must have a negative highly sensitive (urine) pregnancy test as required by local regulations within 24 hours before the first dose of study intervention and should not be at risk of pregnancy throughout the study period.~Exclusion Criteria:~* Gonadotropin-independent (peripheral) precocious puberty: extrapituitary secretion of gonadotropins or gonadotropin-independent gonadal or adrenal sex steroid secretion.~* Non-progressing isolated premature thelarche.~* Presence of an unstable intracranial tumour or an intracranial tumour requiring neurosurgery or cerebral irradiation. Participants with hamartomas not requiring surgery are eligible.~* Prior or current therapy with a GnRHa (Gonadotropin-releasing Hormone Agonist) , medroxyprogesterone acetate, growth hormone or insulin-like growth factor 1 (IGF 1).Use of anticoagulants (heparin and coumarin derivatives) within the 2 weeks prior to the Screening visit.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Triptorelin formulation for Intramuscular injection (IM). (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete